Yahoo Finance Sonoma Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Sonoma Pharmaceuticals (NASDAQ:SNOA) Third Quarter 2024 Results
Key Financial Results
Revenue: US$3.14m (up 6.6% from 3Q 2023).
Net loss: US$866.0k (loss narrowed by 55% from 3Q 2023).
US$0.079 loss per share (improved from US$0.62 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Sonoma Pharmaceuticals EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 17%. Earnings per share (EPS) exceeded analyst estimates by 62%.
Looking ahead, revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Pharmaceuticals industry in the US.
Performance of the American Pharmaceuticals industry.
The company's shares are down 3.2% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Sonoma Pharmaceuticals has 4 warning signs (and 3 which are potentially serious) we think you should know about.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
